Navigation Links
Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Date:2/25/2009

oval submissions targeted within the next three years. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "plans," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR(R); our reliance on products marketed under Food and Drug Administration, or FDA; enforcement policies established in connection with the FDA's Drug Efficacy Study Implementation program; patient, physician and third-party
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
5. Pearl Therapeutics Secures $8 Million in Debt Financing
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Amicus Therapeutics Announces Change to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... that use light, rather than electricity, to move ... energy efficiency is a growing concern as chips, ... components of optical circuits light emitters, modulators, ... build. One promising light source for optical chips ... properties when deposited as a single, atom-thick layer. ...
(Date:9/19/2014)... Florida , September 19, 2014 ... medical technology, development of emerging drug systems and advanced ... Benton, Dickinson and Company (NYSE: BDX ), ... Regado Biosciences Inc. (NASDAQ: RGDO ), Sangamo ... Inc. (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: ...
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... NVAX ) today announced that the Company will ... II human clinical trial in,healthy adult subjects of Novavax,s seasonal ... 11, 2008. , The ... Officer,Dr. Rahul Singhvi and other members of senior management, including ...
... ORLANDO, Fla., Dec. 8 Building on its ... Health today,launched the Pyxis(R) MedStation(R) 4000 and an ... actionable,recommendations to help improve medication safety. , ... 4000 automated medication dispensing system,offers new features that ...
... 8 Interleukin Genetics, Inc. (Amex: ILI ), ... as Vice President, Marketing. Mr. Walker will be responsible ... reporting to the Chief Executive Officer, Lewis H. Bender. ... well as 20 years of industry-related experience. , ...
Cached Biology Technology:Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing 2Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing 3
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2
... published in the Nov. 20 edition of Heredity ... of the evolution of separate sexes, a theory that ... These early stages are not completely understood because the ... titillating separate-sex state too long ago for scientists to ...
... CHICAGO -- The body,s immune system hates strangers. When ... it. This is the problem when people with ... islet cells from a donor pancreas produce robust amounts ... from insulin therapy. However, the immune system tries to ...
... population, and turning research into commercial enterprises, will ... million) investment announced today by the Engineering and ... (TSB) and the Biotechnology and Biological Sciences Research ... two new centres in areas where world-class scientific ...
Cached Biology News:Two from one: Pitt research maps out evolution of genders from hermaphroditic ancestors 2Researcher tricks immune system in diabetic mice 2£20 million to fight virtual crime and treat our ageing population 2£20 million to fight virtual crime and treat our ageing population 3
... Target Retrieval Solution, High pH This ... target retrievel prior to immunohistochemical staining procedures. ... tissue sections mounted on glass slides. For ... 9.9, is especially effective. It should be ...
... very potent Rnase free Ribonuclease ... a broad range of temperatures ... does not inhibit SP6, T7, ... and M-MLV reverse transcriptase or ...
... Dako Target Retrieval Solution, pH 9 ... Tris/EDTA buffer, pH 9, intended for heat-induced ... It is well-suited for use on formalin-fixed, ... Compared with 0.01 mol/L citrate buffer, pH ...
... SeMet White to off-white solid. Increases ... by HPLC. Soluble in H 2 O. ... to use. RTECS EK7713840, CAS 3211-76-5, M.W. ... 13, 8515.Jornot, L., and Junod, A.F. 1995. ...
Biology Products: